Trial · NCT03989206
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
NCT03989206, Phase 3, Completed, Galderma R&D
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis. Trials, record NCT03989206. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03989206
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
- NCT number
- NCT03989206
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 1,935 participants, actual
- Lead sponsor
- Galderma R&D
- Conditions
- Moderate-to-Severe Atopic Dermatitis
- Interventions
- Nemolizumab
- First posted
- 2019-06-18
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence and Severity of TEAEs | Baseline to Week 200 | |
| Primary | Incidence of Serious TEAEs | Baseline to Week 200 | |
| Primary | Incidence and Severity of Adverse Events of Special Interest (AESIs) Throughout the Study | Baseline to Week 200 | |
| Secondary | Proportion of Participants with IGA score = 0-1 at Each Visit | Baseline to Week 200 | |
| Secondary | Proportion of Participants with EASI-75 at Each Visit | Baseline to Week 200 | |
| Secondary | Change and Percent Change From Baseline in Overall Eczema Area and Severity Index (EASI) Score at Each Visit | Baseline to Week 200 | EASI assesses severity and extent of AD signs through a composite score of erythema, induration/population, excoriation, and lichenification. The severity will be assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. The EASI score can range from 0 to 72 with higher scores representing greater severity of atopic dermatitis. |
| Secondary | Proportion of Participants with IGA ≤ 2 at Each Visit | Baseline to Week 200 | |
| Secondary | Change and Percent Change From Baseline in SCORAD Score at Each Visit | Baseline to Week 200 | |
| Secondary | Change and Percent Change From Baseline in Participant-Reported Pruritus Using 10-cm VAS (SCORAD Sub-Component) | Baseline to Week 200 | |
| Secondary | Change and Percent Change From Baseline in Participant-Reported Sleep Loss Using 10-cm VAS (SCORAD Sub-Component) | Baseline to Week 200 |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03989206
GET https://conductscience.org/api/trials/v1/NCT03989206/registered?page=2